ANI Pharmaceuticals (NASDAQ:ANIP) Upgraded at Zacks Research

Zacks Research upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a hold rating to a strong-buy rating in a report issued on Wednesday,Zacks.com reports.

A number of other brokerages have also recently commented on ANIP. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. Guggenheim boosted their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Trading Up 3.7%

NASDAQ ANIP opened at $80.92 on Wednesday. The stock has a 50-day simple moving average of $76.14 and a 200 day simple moving average of $82.00. The company has a market capitalization of $1.81 billion, a PE ratio of 24.08 and a beta of 0.44. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals has a 12 month low of $56.71 and a 12 month high of $99.50.

Insider Activity at ANI Pharmaceuticals

In other news, SVP Krista Davis sold 2,084 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $77.53, for a total value of $161,572.52. Following the sale, the senior vice president directly owned 50,993 shares in the company, valued at $3,953,487.29. This trade represents a 3.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen P. Carey sold 7,312 shares of the business’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $75.50, for a total transaction of $552,056.00. Following the completion of the sale, the chief financial officer directly owned 185,543 shares in the company, valued at approximately $14,008,496.50. This represents a 3.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 27,860 shares of company stock worth $2,111,581. 11.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently modified their holdings of the business. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 202.6% in the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after acquiring an additional 237 shares during the last quarter. Advisors Asset Management Inc. bought a new position in ANI Pharmaceuticals in the first quarter valued at approximately $28,000. Kemnay Advisory Services Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter worth approximately $48,000. State of Wyoming acquired a new position in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $50,000. Finally, CWM LLC raised its stake in shares of ANI Pharmaceuticals by 159.1% during the 3rd quarter. CWM LLC now owns 798 shares of the specialty pharmaceutical company’s stock worth $73,000 after purchasing an additional 490 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.